Lemon BalmvsPEA (Palmitoylethanolamide)

Lemon balm inhibits GABA-transaminase (GABA-T), the enzyme that converts GABA to succinic semialdehyde in the GABA shunt, increasing GABA availability in synaptic terminals and producing anxiolytic effects via GABA-A (alpha2, alpha3 subunits) and GABA-B receptors. Rosmarinic acid provides antioxidant effects via Nrf2 activation and anti-inflammatory effects through COX-2 and NF-kB inhibition. Lemon balm inhibits acetylcholinesterase (AChE) at the catalytic site, mildly increasing acetylcholine in the hippocampus and cortex — explaining cognitive enhancement at moderate doses via muscarinic M1 and nicotinic receptor activation. At higher doses, GABAergic effects dominate, producing sedation useful for sleep. Additional mechanisms may include 5-HT2A antagonism and muscimol-like GABA-A modulation from trace constituents.

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.